VectorBuilder, a genetic engineering specialist based in Guangzhou and nurtured by the state-owned Guangzhou Industrial Investment and Capital Operation Holding Group, has entered into a partnership with Sino Biological, Inc. (SHE: 301047), a global leader in the provision of mammalian cell-based recombinant proteins, antibodies, and related contract research services. This strategic alliance will capitalize on VectorBuilder’s gene delivery expertise and Sino Bio’s R&D and manufacturing capabilities in the biological reagents sector, with the aim of accelerating the translation of R&D achievements and broadening their global market presence. Financial details of the agreement were not disclosed.- Flcube.com
Recent news:
-
Sino Biopharmaceutical Submits NDA for Anlotinib and Penpulimab Combo in HCC to NMPA -
Sihuan Pharmaceutical's Huisheng Pharm Strikes Exclusive Deal for Semaglutide Biosimilar in China -
Innovent Biologics' IBI354 Earns Breakthrough Therapy Designation for Ovarian Cancer Treatment -
CDE Includes Double-Crane's Hydroxocobalamine and Sanofi Genzyme's Fitusiran in Rare Disease Care Plan -
Apeiron Therapeutics Initiates Phase Ia/B Study for GTA182 in Solid Tumors with MTAP Deficiency
